Hello! You're looking at a policy document report on Overton

We track government policy, guidelines, think tank research, working papers and more to help our customers see the impact and influence of their work. Are you interested in seeing what information we have to offer? Request a free trial to our platform.

If you fund, produce or manage research or work to influence policy, we'd love to talk. Learn more on our homepage.

Identifiers

doi
10.1002/14651858.cd009019.pub2

Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children

Flag for USA Guidelines in PubMed Central on December 16th 2013
The Cochrane Database of Systematic Reviews
Abstract Background Asthma is characterised by chronic inflammation of the airways and recurrent exacerbations with wheezing, chest tightness and cough. Treatment with inhaled steroids and bronchodilators often results in good control of symptoms, prevention of further morbidity and mortality and improved quality of life. Several steroids and beta2‐agonists (long‐ and short‐acting) as well as combinations of these treatments are available in a single inhaler to be used once or twice a day, with a separate inhaler for relief of symptoms when needed (for patients in Step three or higher, according to Global Initiative for Asthma (GINA) guidelines). Budesonide/formoterol is also licenced for use as maintenance and reliever therapy from a single inhaler (SiT; sometimes referred to as SMART therapy). SiT can be prescribed at a lower dose than other combination therapy because of the additional steroid doses being received as reliever therapy. It has been suggested that using SiT improves compliance and he...

Topics in this document

Related SDGs

SDG 3: Good Health and Well-being ...
SDG 3: Good Health and Well-being

Target 3.4

Reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being

Target 3.8

Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all

Cites research funded by

Citations

Cited by 14 other policy documents (11 of them are from other policy sources)
 

Recognized names mentioned in this document

Overton only tracks names from certain institutions. Names must have been cited in at least one policy document and their corresponding affiliation has to be found nearby - you can find more details on the help page.

Kayleigh M Kew at St George's, University of London
On page 3 (or quick view this section)
Charlotta Karner at St George's, University of London
On page 3 (or quick view this section)
Kayleigh M Kew at St George's, University of London
On page 3 (or quick view this section)